Cleveland BioLabs, Inc. and Roswell Park Cancer Institute today announced the award of a three-year, $1.2 million Breast Cancer Research Program Breakthrough Award to Roswell Park from the Department of Defense Congressionally Directed Medical Research Program for research into the immunotherapy of metastatic breast cancer with entolimod, a toll-like receptor 5 (TLR5) agonist.

Researchers at Roswell Park Cancer Institute (RPCI) have made new findings about the causes and impacts of RNA modification or “editing.” Innate immune cells — the body’s first line of defense — possess the ability to extensively change genetic information by means of RNA modification as a response to factors associated with inflammation

Researchers at Roswell Park Cancer Institute (RPCI) have identified common inherited gene alterations that appear to make some patients more at risk of neurotoxicity when treated for breast cancer.

Empire State Development (ESD) President, CEO & Commissioner Howard Zemsky and Roswell Park Comprehensive Cancer Center Chief Executive Officer and President Dr. Candace Johnson today announced that following the NYS Trade Mission to Cuba, Roswell Park Cancer Institute in Buffalo has signed an agreement with Cuba’s Center for Molecular Immunology (CIM) to develop a unique lung cancer vaccine with a clinical trial in the United States.

Roswell Park Cancer Institute (RPCI) researchers examined the characteristics of genetic variants in human toll-like receptor 5 (TLR5), and have found that these genetic variants may predict antitumor responses to entolimod, an immunotherapeutic agent with antitumor activity.

A first-of-its kind cancer vaccine, SurVaxM, has demonstrated safety and tolerability in patients with recurrent or progressive malignant brain tumors, according to results of a phase I study conducted by Roswell Park Cancer Institute (RPCI) researchers.

Roswell Park Cancer Institute (RPCI) scientists examined genetic risks for breast cancer in two separate multiethnic epidemiologic studies.

The 17 most promising preliminary cancer research projects at Roswell Park Comprehensive Cancer Center recently received more than $1 million in funding generated by donations and fundraising events.